Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)

  • Technology appraisal
  • TA353
  • Published: 

History

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: final scope for consultation (post referral)

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: final matrix for consultation (post referral)

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: NICE response to comments on the draft scope and provisional matrix (post referral)

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: equality impact assessment

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: draft scope for consultation (pre-referral) August 2014

Ovarian (epithelial), fallopian tube, peritoneal cancer (relapsed, platinum-resistant) - bevacizumab [ID684]: provisional matrix (pre-referral) August 2014